In 2023, Paul Lonergan spent extensive time investigating the reason for his persistent throat discomfort. After consultations with multiple doctors, Lonergan was diagnosed with a significant tumor located at the base of his tongue in Toronto. The 68-year-old acknowledged the challenging battle ahead.
Undergoing seven weeks of radiation and chemotherapy, Lonergan faced an arduous treatment regimen that led to periods in the intensive care unit to eliminate all indications of the tumor. Subsequently, a clinical trial provided Lonergan with a “liquid biopsy,” a modern method for detecting cancer using blood tests to identify tumor DNA not visible in conventional scans. Despite successful treatment for his tongue cancer, the testing revealed lingering tumor fragments in Lonergan’s bloodstream, indicating a potential recurrence.
Following experimental immunotherapy, subsequent liquid biopsies confirmed Lonergan’s cancer-free status. However, access to this evolving cancer monitoring technique is limited for most Canadians, mainly available through clinical trials or high-cost private facilities. Dr. Ramy Saleh, a cancer specialist at McGill University Health Centre, highlighted the transformative potential of liquid biopsies in disease surveillance.
In a groundbreaking initiative, a Toronto-based team from the University Health Network (UHN) initiated a large-scale research project to integrate this innovative technology into standard patient care. The project, named SHERLOCK, aims to enhance cancer survivor care by preventing disease recurrence and avoiding unnecessary treatments.
Led by Dr. Lillian Siu from UHN, the clinical trial will offer liquid biopsies to over 7,000 patients who have completed traditional cancer treatments, over a five-year period. Siu emphasized the project’s focus on detecting circulating tumor DNA early to predict cancer relapse, potentially leading to superior treatment outcomes.
The technology behind liquid biopsies, developed over a decade, enables the detection of minute DNA molecules in blood, revolutionizing cancer monitoring. Ongoing research suggests that these tests are effective in identifying residual disease post-surgery and improving patient survival rates.
While liquid biopsies present promising advancements in cancer care, ethical concerns and the need for regular testing remain. Despite recent setbacks in clinical trials, private clinics are offering early screening tests, raising caution about the technology’s rapid adoption.
Dr. Christopher Booth from Queen’s University emphasized the need for continued research to address the challenges and potential of liquid biopsies. As clinical trials expand globally, the hope is for this technology to become a routine practice, benefiting patients and healthcare systems alike.